Roger D. Dansey - 09 Nov 2022 Form 4 Insider Report for Seagen Inc.

Role
President, Research & Development & Chief Medical Officer
Signature
/s/ Jennifer Prosba, for Roger D. Dansey
Issuer symbol
N/A
Transactions as of
09 Nov 2022
Net transactions value
$0
Form type
4
Filing time
14 Nov 2022, 17:15:18 UTC
Previous filing
19 Oct 2022
Next filing
16 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGEN Non-Qualified Stock Option (Right to Buy) Award $0 +275,000 $0.000000 275,000 09 Nov 2022 Common Stock 275,000 $137.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options are subject to performance vesting in tranches tied to price targets for shares of the Issuer's common stock generally achievable on specified timelines on or before December 31, 2028 or an earlier change of control of the Issuer. Each such tranche will time-vest 1/3 on the date of performance vesting, 1/3 on the 9 month anniversary of performance vesting and 1/3 on the 18 month anniversary of performance vesting.

Remarks:

President, Research & Development & Chief Medical Officer